---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-094733"
form_type: "8-K"
ticker: null
cik: "0001183765"
company_name: "Molecular Templates, Inc."
filed_at: "2024-04-12T23:59:59+00:00"
generated_at: "2026-06-03T23:16:36.934868+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Molecular Templates cuts 30% of workforce; CMO Maurizio Voi to depart April 30

## Summary
- Board approved reduction in force of ~30% to extend resources for clinical studies of MT-6402, MT-8421, MT-0169.
- Estimated pre-tax charges of ~$0.1M for legal fees and termination costs; expected completion by end of April 2024.
- Chief Medical Officer Maurizio Voi, M.D. will cease role effective April 30, 2024 in connection with the reduction.

## SEC filing metadata
- accession: 0001193125-24-094733
- form_type: 8-K
- cik: 0001183765
- company_name: Molecular Templates, Inc.
- filed_at: 2024-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1183765/000119312524094733/0001193125-24-094733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1183765/000119312524094733/d827658d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-094733
- JSON: https://secwatch.observer/filing/0001193125-24-094733.json
- Plain text: https://secwatch.observer/filing/0001193125-24-094733.txt

## Key facts
- Executive change
  Maurizio Voi departed as Chief Medical Officer at Molecular Templates, Inc..
  - Action: ceased to serve
  - Role: Chief Medical Officer
  source text: Effective April 30, 2024 and in connection with the Reduction in Force, Maurizio Voi, M.D. will cease to serve as the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1183765/000119312524094733/0001193125-24-094733-index.htm
- Restructurings & Charges
  Molecular Templates, Inc. announced a restructuring with charges of approximately $0.1 million (approximately 30%).
  - Type: restructuring
  - Charge: approximately $0.1 million
  - Headcount: approximately 30%
  source text: On April 11, 2024, the Board of Directors of Molecular Templates, Inc. (the “Company” or “Molecular Templates”) approved a reduction in force (the “Reduction in Force”) in order to extend its resources to better position the organization and to allow the Company to continue to support its clinical studies for MT-6402, MT-8421 and MT-0169. The Reduction in Force would reduce the Company’s current workforce by approximately 30%. The Company estimates that it will incur aggregate pre-tax charges of approximately $0.1 million in connection with the Reduction in Force, primarily consisting of legal fees and other related termination costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1183765/000119312524094733/0001193125-24-094733-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.